2007'09.18.Tue
Swedish Pharmaceutical Company Oasmia to Next Level: Increased Availability of Oasmia Shares for Investors
September 18, 2007
UPPSALA, Sweden, Sept. 18 /Xinhua-PRNewswire/ -- Oasmia
Pharmaceutical is being listed on NGM Equity in Sweden on
September 18th 2007. This provides private and
institutional shareholders with a better place to trade in
the company's shares.
( Logo:
http://www.newscom.com/cgi-bin/prnh/20070918/273312 )
Oasmia develops the drugs of the future in human and
veterinary medicine. Oasmia is a pharmaceutical company
based on the most recent ideas in bio-organic chemistry.
The business concept is to improve the treatment of serious
diseases, with emphasis on oncology. This is done by
developing substances that create a new generation of
effective drugs for different fields of therapy.
Oasmia is now ready to move forward to provide
financial institutions and large investors with an
interesting, long-term investment opportunity.
"Our product portfolio within oncology is very
strong, and we are in the near future approaching the
veterinary market with a revolutionary cancer therapy for
dogs.
"The positive development means that Oasmia is
becoming a more and more attractive investment opportunity
and that the company will benefit from being listed on NGM
Equity," says Julian Aleksov, CEO of Oasmia.
For more information and downloading of the Listing
prospectus, please visit our website http://www.oasmia.com
More information is available at http://www.ngm.se or
http://www.oasmia.com
About Oasmia Pharmaceutical
Oasmia Pharmaceutical is a pharmaceutical company that
specialises in the treatment of severe diseases. A
pharmaceutical company based on the latest concepts in
bio-organic chemistry. The main idea is to improve the
treatment of serious diseases. Primarily, this development
is in oncology and treatment with cytostatics but Oasmia
also conducts research in antibiotics, asthma and
neurological diseases. Oasmia has in-house production
capacity of pharmaceuticals for clinical trials, both
company related and others. Oasmia has developed several
products based on existing pharmaceuticals in a new
environment, which leads to whole new solutions for cancer
treatment. These products give Oasmia a solid product
portfolio within oncology with several products in
clinical or pre-clinical phase.
For more information, please contact:
Maria Lunden
Oasmia Pharmaceutical
Tel: +46-18-50-54-40
Email: info@oasmia.com
Website: http://www.oasmia.com
PR
Post your Comment
広告
ブログ内検索
アーカイブ
カウンター